<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894606</url>
  </required_header>
  <id_info>
    <org_study_id>THYMO B (RB 13.072)</org_study_id>
    <nct_id>NCT02894606</nct_id>
  </id_info>
  <brief_title>Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients</brief_title>
  <acronym>THYMO B</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <brief_summary>
    <textblock>
      The investigators expect to better characterise B cell subpopulation and functional
      properties early after graft, to analyse effect of induction therapy (thymoglobulin versus
      basiliximab) on B cells, and to compare this B cell profiles with those obtained in our
      previous study in patients with chronic Antibody Mediated Rejection (cAMR)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The distribution of mature blood B cells subpopulations will be compared between the 2 groups</measure>
    <time_frame>one year after renal transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proliferation of freshly isolated cells T in presence of autologous B cells will be compared between the 2 groups.</measure>
    <time_frame>one year after renal transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum B-cell activating factor (BAFF) concentration comparison between the two groups</measure>
    <time_frame>one year after renal transplant</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Thymoglobulin Induction</arm_group_label>
    <description>Patient receiving thymoglobulin as an induction therapy for renal transplant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basiliximab Induction</arm_group_label>
    <description>Patient receiving basiliximab as an induction therapy for renal transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin Induction</intervention_name>
    <description>The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.</description>
    <arm_group_label>Thymoglobulin Induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab Induction</intervention_name>
    <description>The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.</description>
    <arm_group_label>Basiliximab Induction</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        kidney graft recipients from two French renal transplantation centers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years old

          -  Recipient of a renal allograft

          -  Patient receiving either basiliximab or thymoglobulin as in induction therapy for
             renal transplant

          -  Patient presenting a low immunologic risk

          -  Patient not opposed to his (her) study participation

        Exclusion Criteria:

          -  Patient participating in a clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yannick Le meur</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yannick LE MEUR, MD PhD</last_name>
    <email>yannick.lemeur@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick LE MEUR, MD PhD</last_name>
      <email>yannick.lemeur@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Yannick LE MEUR, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Buchler, PhD MD</last_name>
      <email>buchler@med.univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>Immunology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

